Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

36.18 -0.89 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379,626
Open 36.93
Bid (Size) 36.12 (6)
Ask (Size) 36.19 (8)
Prev. Close 37.07
Today's Range 35.75 - 37.64
52wk Range 21.79 - 75.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Small-Cap Stocks that Wall Street Loves for Good Reason
As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves. 
Via InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-10.42%
-10.42%
1 Month
-0.82%
-0.82%
3 Month
-17.15%
-17.15%
6 Month
-45.97%
-45.97%
1 Year
+52.14%
+52.14%

More News

Read More
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
2 Biotech Stocks That Could Soar in December
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Structure Therapeutics
Via Benzinga
The Best-Performing U.S. IPOs Of 2023
Via Talk Markets
IPO watch 2024: Which new stocks will hit the market?
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
Via The Motley Fool
7 Small-Cap Stocks That Wall Street Loves for Good Reason
Via InvestorPlace
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Novo Nordisk's Potential Obesity Drug Rival Structure Therapeutics Stock Tanking Today?
Via Benzinga
Dow Gains Over 50 Points; Nippon Steel To Acquire U. S. Steel
Via Benzinga
Topics Stocks
Exposures US Equities
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Via InvestorPlace
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
Via InvestorPlace
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.